Abstract
Papillon-Lefèvre Syndrome (PLS) is a rare genetic disorder characterized by palmo-plantar hyperkeratosis and aggressive periodontal destruction of both deciduous and permanent dentition. This study examines two unrelated female pediatric patients (aged 4 and 7) to identify the primary microbial drivers of the disease. High levels of Actinobacillus actinomycetemcomitans (A.a.) and corresponding serum antibodies were detected via ELISA and microbial cultures. Treatment strategies, including total deciduous tooth extraction in the younger patient and targeted ofloxacin therapy in the older patient, successfully suppressed A.a. and improved clinical outcomes, identifying A.a. as a key pathogen in PLS-related periodontitis.
The Challenge of Papillon-Lefèvre Syndrome
Papillon-Lefèvre Syndrome presents a devastating "double-hit" clinical profile. Patients suffer from both dermatological abnormalities—specifically thickened, scaly skin on the palms and soles (hyperkeratosis)—and rapid, severe periodontal destruction. Without intervention, this typically leads to the loss of all primary and permanent teeth by early adolescence.
While the skin symptoms are manageable, the dental progression is often relentless. This research sought to clarify the role of the pathogen Actinobacillus actinomycetemcomitans (now known as Aggregatibacter actinomycetemcomitans) and evaluate whether eliminating bacterial reservoirs or using specific antibiotics could halt the bone loss.
Investigating the Microbial Driver
The researchers conducted a longitudinal study of two female patients using a multi-modal approach:
- Clinical & Radiographic Imaging: Measuring pocket depths and using X-rays to quantify bone loss.
- Bacteriological Analysis: Culturing samples from deep periodontal pockets on selective media (TSBV agar) to identify specific pathogens.
- Immunological Assays: Measuring serum antibody (IgG) titers against various bacterial strains using ELISA and immunoblotting to compare immune responses against healthy controls.
Key Insights and Treatment Strategies
The A.a. Connection
Both patients exhibited exceptionally high antibody titers and high percentages of A.a. in their microbial cultures. In one patient, A.a. accounted for up to 26.9% of the total cultivable flora in deep pockets. This strongly suggests that PLS-related bone loss is specifically driven by this pathogen rather than a generalized infection.
The "Reservoir" Hypothesis
In the younger patient (Patient A), all deciduous teeth were extracted before the permanent teeth erupted. This "reset" the oral microbiome; A.a. became undetectable, and the permanent teeth erupted into a healthy environment without the typical inflammation or bone loss associated with PLS.
Antibiotic Specificity
Patient B did not respond to standard therapy or common antibiotics like minocycline or erythromycin. However, ofloxacin (a fluoroquinolone) successfully suppressed A.a. colonies and reduced inflammation, highlighting the necessity of pathogen-specific drug selection in PLS management.
Conclusion and Future Directions
The study demonstrates that aggressive intervention—either through total primary tooth extraction or targeted antibiotic therapy—can suppress A.a. and potentially save a patient's permanent dentition. While limited by a small sample size, these findings underscore the importance of early microbiological diagnosis. Future work has since explored the underlying genetic mutations (specifically in the CTSC gene) that predispose PLS patients to such severe infections.
Summary updated